50848-64-1

Usage

Uses

Geranyl Geranyl Bromide is an intermediate used in the synthesis of 15-cis-Phytoene (P398805), which is an intermediate in the biosynthesis of carotenoids.

Upstream product

• 68931-30-6 1,6,10,14-hexadecatetraen-3-ol, 3,7,11,15-tetramethyl- 
• 1113-21-9 (6E,10E)-geranyllinalool 
• 24034-73-9 Geranylgeraniol 
• 110-86-1 pyridine 
• 7789-60-8 phosphorus tribromide 
• 169121-41-9 ((6E,10E)-3,7,11,15-tetramethylhexadeca-1,6,10,14-tetraen-3-yl acetate) 
• 132513-65-6 3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl acetate 
• 68690-51-7 all-trans-1-benzyloxy-3,7,11,15-tetramethyl-9-p-tolylsulfonyl-2,6,10,14-hexadecatetraene 
• 6138-90-5 geranyl bromide 
• 106-25-2 Nerol 
• 106-28-5 Farnesol 
• 1117-52-8 6,10,14-trimethyl-5,9,13-pentadecatriene-2-on 
• 3675-00-1 methyl (E,E)-farnesoate 
• 689-67-8 pseudo-ionone 

Downstream Products

• 123122-30-5 4-phenylsulfonyl-3,7,11,15,19-pentamethyleicosa-2E,6E,10E,14E,18-pentaen-1-ol 
• 68690-47-1 1-methyl-4-{[(2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl]sulfonyl}benzene 
• 50848-62-9 2,5-bis(methoxymethoxy)-1-methyl-3-<(E,E,E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraenyl>benzene 
• 502-62-5 Lycopersen 
• 142923-97-5 2-acetylamino-3-(3,7,11,15-tetramethyl-hexadeca-2,6,10,14-tetraenylsulfanyl)-propionic acid methyl ester 
• 90123-25-4 Methyl (4E,8E,12E)-5,9,13,17-tetramethyloctadeca-4,8,12,16-tetraenoate 
• 540-05-6 all-(E)-phytofluene 
• 502-63-6 7,8,11,12-Tetrahydrolycopen 
• 1169860-26-7 C₃₃H₅₀O₃ 
• 1169860-32-5 C₄₂H₇₀O₃Si 

Relevant academic research and scientific papers

Evaluation of a cell penetrating prenylated peptide lacking an intrinsic fluorophore via in situ click reaction

Protein prenylation involves the addition of either a farnesyl (C 15) or geranylgeranyl (C20) isoprenoid moiety onto the C-terminus of many proteins. This natural modification serves to direct a protein to the plasma membrane of the

Identification and optimization of quinolone-based inhibitors against cytochrome bd oxidase using an electrochemical assay

A target-focused library of small molecules, containing a set of quinones, quinolones, coumarins, flavonoids and other diverse drugs was screened to identify potential inhibitors of the cytochrome bd-I oxidase from Escherichia coli by means of an electroc

Total synthesis of geranylgeranylglyceryl phosphate enantiomers: Substrates for characterization of 2,3-O-digeranylgeranylglyceryl phosphate synthase

To determine the enantioselectivity of (S)-2,3-di-O-geranylgeranylglyceryl phosphate synthase (DGGGPS) from the thermoacidophilic archaeon Sulfolobus solfataricus, we developed an efficient enantioselective route to the enantiomeric geranylgeranylglyceryl phosphates (R)-GGGP and (S)-GGGP. Previous routes to these substrates involved enzymatic conversions due to the lability of the polyprenyl chains toward common phosphorylation reaction conditions. The synthesis described herein employs a mild trimethyl phosphite/carbon tetrabromide oxidative phosphorylation to circumvent this problem. In contrast to previous results suggesting that only (S)-GGGP can act as the prenyl acceptor substrate, both (R)-GGGP and (S)-GGGP were found to be substrates for DGGGPS.

Substrate specificities of several prenyl chain elongating enzymes with respect to 4-methyl-4-pentenyl diphosphate

In order to develop synthetic methods for biologically active homoallylic terpene sulfates, we examined the applicability and substrate specificities of several prenyl chain elongating enzymes with respect to 4-methyl-4-pentenyl diphosphate (homoIPP). The reaction of dimethylallyl diphosphate with homoIPP by use of Bacillus stearothermophilus (all-trans)-farnesyl diphosphate synthase resulted in efficient yields of cis-(yield: 45.9%) and trans-4,8-dimethylnona-3, 7-dien-1-ol (homoGOH, 25.5%), which has a carbon skeleton of 4,8-dimethylnona-3-en-1-sulfate, an antiproliferative compound from a marine organism (Aiello, A. et al., Tetrahedron, 53, 11489-11492 (1997)). The homoIPP was found to be also active as a homoallylic substrate in place of isopentenyl diphosphate for Sulfolobus acidocaldarius geranylgeranyl diphosphate synthase to give diphosphate of cis- and trans-4,8,12-trimethyltrideca-3,7,11-trien-1-ol, for Micrococcus luteus B-P 26 hexaprenyl diphosphate synthase to give cis- and trans-4,8,12,16-tetramethylheptadeca-3,7,11,15-tetraen-1-ol (homoGGOH), and for Micrococcus luteus B-P 26 undecaprenyl diphosphate synthase to give cis-homoGGOH exclusively.

S-Geranylgeranyl-l-glutathione is a ligand for human B cell-confinement receptor P2RY8

Germinal centres are important sites for antibody diversification and affinity maturation, and are also a common origin of B cell malignancies. Despite being made up of motile cells, germinal centres are tightly confined within B cell follicles. The cues that promote this confinement are incompletely understood. P2RY8 is a Gα13-coupled receptor that mediates the inhibition of migration and regulates the growth of B cells in lymphoid tissues1,2. P2RY8 is frequently mutated in germinal-centre B cell-like diffuse large B cell lymphoma (GCB-DLBCL) and Burkitt lymphoma1,3–6, and the ligand for this receptor has not yet been identified. Here we perform a search for P2RY8 ligands and find P2RY8 bioactivity in bile and in culture supernatants of several mouse and human cell lines. Using a seven-step biochemical fractionation procedure and a drop-out mass spectrometry approach, we show that a previously undescribed biomolecule, S-geranylgeranyl-l-glutathione (GGG), is a potent P2RY8 ligand that is detectable in lymphoid tissues at the nanomolar level. GGG inhibited the chemokine-mediated migration of human germinal-centre B cells and T follicular helper cells, and antagonized the induction of phosphorylated AKT in germinal-centre B cells. We also found that the enzyme gamma-glutamyltransferase-5 (GGT5), which was highly expressed by follicular dendritic cells, metabolized GGG to a form that did not activate the receptor. Overexpression of GGT5 disrupted the ability of P2RY8 to promote B cell confinement to germinal centres, which?indicates that GGT5 establishes a GGG gradient in lymphoid tissues. This work defines GGG as an intercellular signalling molecule?that is involved in organizing and controlling germinal-centre responses. As the P2RY8 locus is modified in several other types of?cancer in addition to GCB-DLBCL and Burkitt lymphoma, we speculate that GGG might have organizing and growth-regulatory roles in multiple human tissues.

Coumarin derivatives for cancer therapy

The disclosure provides methods and compositions for treating and preventing cancer using 6-substituted coumarin derivatives. The coumarin derivatives of the disclosure have substituents at the 6-position with five carbon atoms or greater. The coumarin derivatives may be further substituted and may be 3,4-dihydrocoumarins. In preferred embodiments, the coumarin derivatives of the disclosure are used to treat pancreatic cancer.

GGA DERIVATIVES

This invention relates to geranylgeranyl acetone (GGA) derivatives, pharmaceutical compositions comprising GGA derivatives and the use of GGA derivatives.

METHODS FOR TREATING NEURON DAMAGE

This invention relates to the use of geranylgeranyl acetone (GGA), its isomers, and GGA derivatives in a method for for treating a disease in a subject mediated in part by miRNA-378 or miRNA-711 increased activity comprising administering to the subject a therapeutically effective amount of 5-trans-GGA or a derivative thereof.

GGA AND GGA DERIVATIVES COMPOSITIONS THEREOF AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES INCLUDING PARALYSIS INCLUDING THEM

This invention relates to geranylgeranyl acetone (GGA) derivatives and the use of GGA, its isomers, and GGA derivatives in methods for inhibiting neural death, increasing neural activity, increasing axon growth and cell viability, and increasing the survival rate of subjects administered the GGA or GGA derivatives.

GERANYLGERANYLACETONE DERIVATIVES

Provided herein are geranylgeranylacetone derivatives and methods of using them.